Any current/future new fundraising through debt or equity?

There is no explicit mention on Page 24 or the provided excerpts about any current or future fundraising plans through debt or equity. The management discusses expansion plans including opening new clinics and hospitals, but does not specify raising funds via debt or equity. Investments mentioned, such as the Dubai venture, involve licensing and marketing costs rather than large fixed-asset investments or capital raises. The company is focusing on organic growth and managing costs like marketing and manpower to improve profitability. No direct reference to any planned capital raising activitie

Any current/future capex/capital investment/strategic investment?

The company is expanding its hospital footprint, targeting to open 10 hospitals in total. The third hospital is already underway in collaboration with AMTZ, Andhra Pradesh Medical Tech Zone. Talks are ongoing with a few sick nature cure hospitals for potential operational management contracts or hospital franchises to expand the Madhavbaug brand. Clinic network expansion is continuing, with about 50 new clinics opened recently, including franchise-owned and company-operated (FOCO) and company-owned (COCO) models, increasing fixed costs but expecting future returns. Investment in Dubai is

Future growth expectations in sales/revenue/volumes?

The company targets a CAGR growth of approximately 25% over the next couple of years. Revenue is expected to roughly double in a couple of years from the current run rate (~INR 50 crores). Clinic count increased from 302 to 350 by September 30, now at 358, signaling ongoing expansion. Aim to expand to about 1000 clinics with each clinic targeted to achieve around INR 1 crore turnover annually. Plans to open 10 hospitals, with two currently operational in Nagpur and Khopoli; new hospital projects underway. Focus on increasing patient footfall in clinics and hospitals as a key growth driver. New

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets a 25% CAGR growth over the next couple of years. Revenue is expected to double in the next 2-3 years with expansion in clinics, hospitals, product launches (like Madhavprash gummies), and new markets (e.g., Dubai). EBITDA margins currently under pressure due to increased manpower and marketing for clinic expansion but expected to improve to 8-9% by year-end. Long-term EBITDA margin target is around 10-12% as operating leverage improves with scale. Hospitals have strong individual margins (20-25% EBITDA) and are expected to contribute more as bed capacity increases. With bra

Vaidya Sane Ayurved Laboratories LtdQ2 FY24Healthcare Equipment & Supplies

Vaidya Sane Ayurved Laboratories Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹136P/E: 15.9Market Cap: ₹143 CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

The company targets a CAGR growth of approximately 25% over the next couple of years.
Revenue is expected to roughly double in a couple of years from the current run rate (~INR 50 crores).
Clinic count increased from 302 to 350 by September 30, now at 358, signaling ongoing expansion.
Aim to expand to about 1000 clinics with each clinic targeted to achieve around INR 1 crore turnover annually.
Plans to open 10 hospitals, with two currently operational in Nagpur and Khopoli; new hospital projects underway.
Focus on increasing patient footfall in clinics and hospitals as a key growth driver.
New product launches such as Madhavprash gummies and international expansion (e.g., Dubai franchise clinics) expected to boost growth.
Utilization of existing Panchakarma service capacity (~50%-60%) presents additional growth opportunity without adding clinics.

Margin guidance

Category 1

The company targets a 25% CAGR growth over the next couple of years.
Revenue is expected to double in the next 2-3 years with expansion in clinics, hospitals, product launches (like Madhavprash gummies), and new markets (e.g., Dubai).
EBITDA margins currently under pressure due to increased manpower and marketing for clinic expansion but expected to improve to 8-9% by year-end.
Long-term EBITDA margin target is around 10-12% as operating leverage improves with scale.
Hospitals have strong individual margins (20-25% EBITDA) and are expected to contribute more as bed capacity increases.
With brand acceptance, marketing and expansion costs will reduce, supporting margin expansion.
New franchise models and utilization of existing clinic capacity (currently 50-60%) offer upside to profitability.
Break-even timelines for new hospitals are 4-5 months to 1-2 years, indicating scalable profitability in new ventures.

See what Vaidya Sane Ayurved Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention on Page 24 or the provided excerpts about any current or future fundraising plans through debt or equity.
The management discusses expansion plans including opening new clinics and hospitals, but does not specify raising funds via debt or equity.
Investments mentioned, such as the Dubai venture, involve licensing and marketing costs rather than large fixed-asset investments or capital raises.
The company is focusing on organic growth and managing costs like marketing and manpower to improve profitability.
No direct reference to any planned capital raising activities was made in the Q&A or closing remarks.

Order book

The transcript provided from the PDF does not explicitly mention details on the current or expected order book or pending orders for Vaidya Sane Ayurved Laboratories Limited. The discussion focuses primarily on: - Clinic expansion targets (aiming for approximately 1000 clinics). - Hospital expansion plans including up to 10 hospitals. - Growth strategy including organic clinic growth and new hospital tie-ups. - Capacity utilization of existing Panchakarma clinics (~50%-60% currently). - Operational challenges impacting EBITDA margins related to manpower and marketing. - Business development such as new hospital agreements and ongoing talks. - No specific numerical data or details on order book or pending orders disclosed during the call. Hence, the transcript does not provide clear figures or an explicit update on order book or pending orders status.

See what Vaidya Sane Ayurved Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is expanding its hospital footprint, targeting to open 10 hospitals in total. The third hospital is already underway in collaboration with AMTZ, Andhra Pradesh Medical Tech Zone.
Talks are ongoing with a few sick nature cure hospitals for potential operational management contracts or hospital franchises to expand the Madhavbaug brand.
Clinic network expansion is continuing, with about 50 new clinics opened recently, including franchise-owned and company-operated (FOCO) and company-owned (COCO) models, increasing fixed costs but expecting future returns.
Investment in Dubai is planned, focusing on licensing products and brand awareness rather than fixed assets. Doctors licensed in Dubai will run franchise clinics, with insurance coverage being a key strategic opportunity.
No large fixed asset investment planned for Dubai; capital expenditure is mainly related to clinic and hospital expansions within India.

Track Vaidya Sane Ayurved Laboratories Ltd — get its next earnings analysis in your feed

How does Vaidya Sane Ayurved Laboratories Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisVaidya Sane Ayurved Laboratories Ltd

Rev 2Mar 1

See where Vaidya Sane Ayurved Laboratories Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Vaidya Sane Ayurved Laboratories Ltd rank in Healthcare Equipment & Supplies?

Compare Vaidya Sane Ayurved Laboratories Ltd against every Healthcare Equipment & Supplies company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Vaidya Sane Ayurved Laboratories Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Galaxy Medicare (Q2 FY27)
Revenue from Operations (₹ Mn): . Key investor presentation takeaways from Galaxy Medicare's Q2 FY27 investor presentation — and how it ranks against sector pee
Nureca Ltd (Q2 FY27)
Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's
Aprameya Engineering Ltd (Q2 FY26)
H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26
Nureca Ltd (Q2 FY26)
Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

Compare:vs Poly Medicure Ltd vs Molbio Diagnosti vs Sahajanand Medical Technologies Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →